Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E-cadherin: a differentiation marker in thyroid malignancies

G Brabant1, C Hoang-Vu, Y Cetin

  • 1Department of Clinical Endocrinology, Medizinische Hochschule, Hannover, Germany.

Cancer Research
|October 15, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Endocarditis and ischemic stroke of rare cause].

Innere Medizin (Heidelberg, Germany)·2024
Same author

Malignancy rates in thyroid nodules: a long-term cohort study of 17,592 patients.

European thyroid journal·2022
Same author

[Thyroid hormone therapy in old age].

Der Internist·2020
Same author

Angiotensin converting enzymes ACE and ACE2 in thyroid cancer progression.

Neoplasma·2019
Same author

Assessment of fetal head engagement with transperineal ultrasound: Searching for the cutoff level.

Journal of gynecology obstetrics and human reproduction·2018
Same author

Mild Thyrotoxicosis Leads to Brain Perfusion Changes: An Arterial Spin Labelling Study.

Journal of neuroendocrinology·2016
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

E-cadherin (uvomorulin) expression is reduced in thyroid cancers, particularly in advanced stages. Both gene expression and posttranscriptional control of E-cadherin appear impaired in these malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • E-cadherin (uvomorulin) is a crucial Ca(2+)-dependent cell adhesion molecule essential for normal epithelial function.
  • Loss of E-cadherin expression is implicated in tumor invasion and metastasis.
  • Understanding E-cadherin expression in thyroid neoplasms is vital for diagnosing and treating thyroid cancer.

Purpose of the Study:

  • To investigate the expression of E-cadherin in normal and neoplastic human thyroid follicular epithelium.
  • To correlate E-cadherin expression levels with different types of thyroid disorders and cancer stages.
  • To explore potential mechanisms regulating E-cadherin expression in thyroid malignancies.

Main Methods:

  • Northern blot analysis to quantify E-cadherin mRNA levels.

Related Experiment Videos

  • Immunofluorescence staining using anti-E-cadherin monoclonal antibody on frozen tissue sections.
  • Analysis of E-cadherin expression in normal thyroid, benign disorders, and various types of thyroid carcinomas (anaplastic, papillary, follicular, Hürthle cell).

    • Main Results:

    • Normal and benign thyroid tissues showed high E-cadherin mRNA and surface staining.
    • Anaplastic thyroid carcinomas exhibited very low or absent E-cadherin expression.
    • Papillary and follicular carcinomas displayed variable E-cadherin mRNA levels and heterogeneous/reduced surface staining; some tumors had low protein despite high mRNA.
    • Hürthle cell tumors showed reduced, intracellular E-cadherin immunoreactivity.
    • Relapsing and metastatic thyroid carcinomas had low or absent E-cadherin expression.
    • A correlation was observed between E-cadherin and thyrotropin receptor expression levels.

    Conclusions:

    • E-cadherin expression is significantly reduced or lost in various human thyroid malignancies, especially in advanced and metastatic disease.
    • Both gene expression and posttranscriptional regulation of E-cadherin may be impaired in thyroid cancers.
    • Altered E-cadherin expression patterns in thyroid neoplasms suggest a role in tumor progression and invasion.